Government would be ‘foolish’ to ignore palliative care warnings over assisted dying
Committee chair Layla Moran says doctors’ concerns about potential impact on vulnerable patients must be heeded
Related Articles
Thrombosis and Hemostasis Conference | ISTH 2025 Congress
The ISTH 2025 Congress is the premier international medical and scientific conference for experts in the fields of thrombosis, hemostasis and vascular biology. Join us…
CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations
Abstract. Multiple chimeric antigen receptor (CAR) T-cell therapies are US Food and Drug Administration–approved, and several are under development. Althou
Long-Term Follow up of BMT CTN 0901, a Randomized Phase III Trial Comparing Myeloablative (MAC) to Reduced Intensity Conditioning (RIC) Prior to Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML) or Myelodysplasia (MDS) (MAvRIC Trial)
BMT CTN 0901 enrolled patients with MDS (N=54) or AML (N=218) (median age of 55 years) who had < 5% marrow blasts by morphology prior…
Paper: Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial
Program: Late-breaking Abstracts Session: Late-Breaking Abstracts Session Hematology Disease Topics & Pathways: Research, Clinical trials, Lymphomas, Non-Hodgkin lymphoma, Clinical Research, B Cell lymphoma, Diseases, Lymphoid…
Updated analysis of EMN02 demonstrated overall survival benefit to early ASCT for multiple myeloma
Blood Cancer Journal – Updated analysis of EMN02 demonstrated overall survival benefit to early ASCT for multiple myeloma
Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission
Recent studies have suggested that chimeric antigen receptor (CAR) T cells be moved to second-line therapy for some patients with relapsed diffuse large B-cell lymphoma…
Why bone marrow transplants are becoming less common
Bone marrow transplants, long a mainstay of blood cancer treatments, are becoming less common in favor of options like CAR-T therapy
When Can we Feed after a Gastrointestinal Bleed?
Current Gastroenterology Reports – Gastrointestinal (GI) bleeding can carry minimal or significant risk for recurrent hemorrhage. Timing of feeding after GI bleeding remains an area…
New Risk Classification Stratifies Outcomes in Older Intensively Treated Patients with AML | ASH Clinical News | American Society of Hematology
Lara C. Pullen, PhD, is a freelance medical writer in Chicago, Illinois. The new AML60+ classification provides prognostic information for intensively treated patients 60 years…
Critical Recent NCCN Guideline Updates Affect Dozens of Malignancies
Experts detail how recent NCCN guideline changes in dozens of tumor types are affecting their practices, and we gather all the NCCN updates in a…
